Next Generation Sequencing of GATC Biotech AG Accredited by German DAkkS
GATC Biotech customers can expect highest quality standards for Next Generation Sequencing projects from official accreditation
Konstanz, Germany, December 3, 2012 / B3C newswire / – Being the first in Europe, the Next Generation Sequencing Laboratories of the Constance Genome and Diagnostics Centre has been accredited according to ISO 17025 from the national accreditation body for the Federal Republic of Germany (DAkks). The independent governmental institution has acknowledged the high quality standard of the sequencing service on technology platforms Illumina HiSeq and Roche GSFLX sequencing.
“As an accredited service provider we assure our customers the latest state-of-the-art standards in our methods, technologies and data quality at all times. This is especially important to our customers from the industry or diagnostics. A reliable and continuously high quality of the analysis service is of great importance to them. The accreditation allows all customers to compare the quality of service providers on the international sequencing market”, explains Dr. Marcus Benz, COO of GATC Biotech AG.
“While inspecting the laboratories, we met a very qualified and motivated team that has developed a high competency for the complex analysis. Apart from the staff and the excellent equipment, the LIMS system has to be highlighted. This in-house developed software system allows a wide monitoring of the processes and contributes especially to internal quality management”, says the DAkkS expert.
Since June 2012, the accreditation according to ISO 17025 has been official and has been confirmed by extensive audits. The Genome and Diagnostics Centre of GATC Biotech in Constance meets essential requirements for the competence of analysis and calibration laboratories such as DIN EN ISO/IEC 17025, DIN EN ISO 9001 and all further conditions. The compliance of standards is monitored by the DAkkS regularly.
About GATC Biotech
GATC Biotech is Europe’s leading service provider of DNA sequencing. For over two decades the company has offered sequencing and bioinformatics solutions for single samples, transcriptomes and regulomes, up to whole genomes. GATC has sequenced more than 5 million samples, ten thousands of bacterial, plant or other whole genomes as well as hundreds of whole human genomes for its more than 10.000 academic and industrial customers worldwide.
GATC Biotech offers true multiplatform sequencing using all leading sequencing technologies in its own labs. GATC´s acknowledged bioinformatics solutions allow high-end data analysis for its customers in pharmaceutical, diagnostic, chemical or food industries as well as in academics. As an Agilent and Illumina Certified Service Provider, GATC enables full compliance with latest state-of-the-art standards. GATC acts as a supplier for the ICGC, the International Cancer Genome Consortium.
GATC´s subsidiary LifeCodexx emphasizes the development of clinically validated molecular diagnostic tests and offers a risk-free alternative to common invasive examination methods such as amniocentesis.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance